SCHEME OF EXAMINATION
&
DETAILED SYLLABUS
For

MASTER OF PHARMACY

(PHARMACEUTICS (MPH))
As per (PCI)

(W.e.f. 2021-2022)

KALINGA UNIVERSITY

Faculty of Pharmacy
Kalinga University, Naya Raipur
Chhattisgarh

Teaching and Evaluation Scheme

SEMESTER- I (M. Pharmacy- Pharmaceutics)

S. N.	Cat.	Paper Code	Subject	L	T	P/D	Credits	Evaluation Scheme				
								Internal Assessment			ESE	Subject Total
								CT	TA	Total		
	Theory:											
1		MPH101T	Modern Pharmaceutical Analytical Techniques	4	-	-	4	15	10	25	75	100
2		MPH102T	Drug Delivery System	4	-	-	4	15	10	25	75	100
3		MPH103T	Modern Pharmaceutics	4	-	-	4	15	10	25	75	100
4		MPH104T	Regulatory Affair	4	-	-	4	15	10	25	75	100
		Labs:										
1		MPH105P	Pharmaceutics Practical I	-	-	12	6	30	20	50	100	150
		MPH106P	Seminar/ Assignments	-	7	-	4	-	-	-	-	100
Total				**16**	**7**	**12**	**26**					**650**
	Total work Load=35						**Total Credit = 26**					

Teaching and Evaluation Scheme

SEMESTER- II (M. Pharmacy- Pharmaceutics)

S. N.	Cat.	Paper Code	Subject	L	T	P/D	Credits	Evaluation Scheme				
								Internal Assessment			ESE	Subject Total
								CT	TA	Total		
	Theory:											
1		MPH201T	Molecular Pharmaceutics (Nano Tech and Targeted DDS)	4	-	-	4	15	10	25	75	100
2		MPH202T	Advanced Biopharmaceutics& Pharmacokinetics	4	-	-	4	15	10	25	75	100
3		MPH203T	Computer Aided Drug Delivery System	4	-	-	4	15	10	25	75	100
4		MPH204T	Cosmetic and Cosmeceuticals	4	-	-	4	15	10	25	75	100
		Labs:										
1		MPH205P	Pharmaceutics Practical II	-	-	12	6	30	20	50	100	150
		MPH206P	Seminar/ Assignments	-	7	-	4	-	-	-	-	100
Total				**16**	**7**	**12**	**26**					**650**
	Total work Load=35						**Total Credit = 26**					

Teaching and Evaluation Scheme
SEMESTER- III (M. Pharmacy- Pharmaceutics)

S. N.	Category	Paper Code	Subject	L	T	P/D	Credits	Evaluation Scheme				
								Internal Assessment			ESE	Subject Total
								CT	TA	Total		
	Theory:											
1		MRM 301T	Research Methodology and Biostatistics	4	-	-	4	15	10	25	75	100
2		MPH302P	Journal club	1	-	-	1	-	-	25	-	25
3		MPH303P	Discussion / Presentation (Proposal Presentation)	2	-	-	2	-	-	50	-	50
4		MPH304P	Research Work	28	-	-	14	-	-	-	350	350
Total				**35**			**21**	-	-			**525**
	Total work Load=35						**Total Credit = 21**					

Teaching and Evaluation Scheme

SEMESTER- IV (M. Pharmacy- Pharma

S. N.	Category	Paper Code	Subject	L	T	P/D	Credits	Evaluation Scheme				
								Internal Assessment			ESE	Subject Total
								CT	TA	Total		
	Theory:											
1		MPH401P	Journal club	1	-	-	1	-	-	25	-	25
2		MPH402P	Discussion / Presentation (Proposal Presentation)	3	-	-	3	-	-	75	-	75
3		MPH403P	Research Work	31	-	-	16	-	-	-	400	400
Total				**35**	-	-	**20**	-	-	-	-	**500**
	Total work Load=35						**Total Credit = 20**					

PHARMACEUTICS (MPH)

MPH 101 T. MODERN PHARMACEUTICAL ANALYTICAL TECHNIQUES

Scope: This subject deals with various advanced analytical instrumental techniques for identification, characterization and quantification of drugs. Instruments dealt are NMR, Mass spectrometer, IR, HPLC, GC etc.

Objectives : After completion of course student is able to know,

- Chemicals and Excipients
- The analysis of various drugs in single and combination dosage forms
- Theoretical and practical skills of the instruments

COURSE CONTENT

UNIT	CONTENT	No. of Hrs.
I	a. **UV-Visible spectroscopy**: Introduction, Theory, Laws, Instrumentation associated with UV-Visible spectroscopy, Choice of solvents and solvent effect and Applications of UV Visible spectroscopy. b. **IR spectroscopy**: Theory, Modes of Molecular vibrations, Sample handling, Instrumentation of Dispersive and Fourier - Transform IR Spectrometer, Factors affecting vibrational frequencies and Applications of IR spectroscopy c. **Spectroflourimetry**: Theory of Fluorescence, Factors affecting fluorescence, Quenchers, Instrumentation and Applications of fluorescence spectrophotometer. **d. Flame emission spectroscopy and Atomic absorption spectroscopy**: Principle, Instrumentation, Interferences and Applications.	**11**
II	**NMR spectroscopy**: Quantum numbers and their role in NMR, Principle, Instrumentation, Solvent requirement in NMR, Relaxation process, NMR signals in	**11**

	various compounds, Chemical shift, Factors influencing chemical shift, Spin-Spin coupling, Coupling constant, Nuclear magnetic double resonance, Brief outline of principles of FT-NMR and ^{13}C NMR. Applications of NMR spectroscopy.	
III	**Mass Spectroscopy**: Principle, Theory, Instrumentation of Mass Spectroscopy, Different types of ionization like electron impact, chemical, field, FAB and MALDI, APCI, ESI, APPI Analyzers of Quadrupole and Time of Flight, Mass fragmentation and its rules, Meta stable ions, Isotopic peaks and Applications of Mass spectroscopy	**11**
IV	**Chromatography**: Principle, apparatus, instrumentation, chromatographic parameters, factors affecting resolution and applications of the following: a) Paper chromatography b) Thin Layer chromatography c) Ion exchange chromatography d) Column chromatography e) Gas chromatography f) High Performance Liquid chromatography g) Affinity chromatography	**11**
V	a. **Electrophoresis:** Principle, Instrumentation, Working conditions, factors affecting separation and applications of the following: i) Paper electrophoresis ii) Gel electrophoresis iii) Capillary electrophoresis iv) Zone electrophoresis v) Moving boundary electrophoresis vi) Iso electric focusing b. **X ray Crystallography**: Production of X rays, Different X ray diffraction methods, Bragg,,s law, Rotating crystal technique, X ray powder technique, Types of crystals and applications of Xray diffraction. c. **Immunological assays** : RIA (Radio immuno assay), ELISA, Bioluminescence assays.	**16**

REFERENCES

1. Spectrometric Identification of Organic compounds - Robert M Silverstein, Sixth edition, John Wiley & Sons, 2004.

2. Principles of Instrumental Analysis - Doglas A Skoog, F. James Holler, Timothy A. Nieman, 5th edition, Eastern press, Bangalore, 1998.

3. Instrumental methods of analysis – Willards, 7th edition, CBS publishers.

4. Practical Pharmaceutical Chemistry – Beckett and Stenlake, Vol II, 4th edition, CBS Publishers, New Delhi, 1997.

5. Organic Spectroscopy - William Kemp, 3rd edition, ELBS, 1991.

6. Quantitative Analysis of Drugs in Pharmaceutical formulation - P D Sethi, 3rd Edition, CBS Publishers, New Delhi, 1997.

7. Pharmaceutical Analysis- Modern methods – Part B - J W Munson, Volume 11, Marcel Dekker Series

MPH 102T. DRUG DELIVERY SYSTEMS

SCOPE: This course is designed to impart knowledge on the area of advances in novel drug delivery systems.

OBJECTIVES: Upon completion of the course, student shall be able to understand

- The various approaches for development of novel drug delivery systems.
- The criteria for selection of drugs and polymers for the development of delivering system
- The formulation and evaluation of Novel drug delivery systems..

COURSE CONTENT

UNIT	CONTENT	No. of Hrs.
I	**Sustained Release(SR) and Controlled Release (CR) formulations**: Introduction & basic concepts, advantages/ disadvantages, factors influencing, Physicochemical & biological approaches for SR/CR formulation, Mechanism of Drug Deliveryfrom SR/CR formulation. Polymers: introduction, definition, classification, properties and application Dosage Forms for Personalized Medicine: Introduction, Definition, Pharmacogenetics, Categories of Patients for Personalized Medicines: Customized drug delivery systems, Bioelectronic Medicines, 3D printing of pharmaceuticals, Telepharmacy.	**10**
II	**Rate Controlled Drug Delivery Systems**: Principles & Fundamentals, Types, Activation; Modulated Drug Delivery Systems;Mechanically activated, pH activated, Enzyme activated, and Osmotic activated Drug Delivery Systems Feedback regulated Drug Delivery Systems; Principles & Fundamentals.	**10**
III	**Gastro-Retentive Drug Delivery Systems**: Principle, concepts advantages and disadvantages, Modulation of GI transit time approaches to extend GI transit. **Buccal Drug Delivery Systems**: Principle of muco adhesion, advantages and	**16**

	disadvantages, Mechanism of drug permeation, Methods of formulation and its evaluations. **Occular Drug Delivery Systems**: Barriers of drug permeation, Methods to overcome barriers.	
IV	Transdermal Drug Delivery Systems: Structure of skin and barriers, Penetration enhancers, Transdermal Drug Delivery Systems, Formulation and evaluation.	**10**
V	**Protein and Peptide Delivery**: Barriers for protein delivery. Formulation and Evaluation of delivery systems of proteins and other macromolecules. **Vaccine delivery systems**: Vaccines, uptake of antigens, single shot vaccines, mucosal and transdermal delivery of vaccines.	**14**

REFERENCES

1. Y W. Chien, Novel Drug Delivery Systems, 2nd edition, revised andexpanded,Marcel Dekker, Inc., New York, 1992.

2. Robinson, J. R., Lee V. H. L, Controlled Drug Delivery Systems, MarcelDekker,Inc., New York, 1992.

3. Encyclopedia of controlled delivery, Editor- Edith Mathiowitz, Published byWileyInterscience Publication, John Wiley and Sons, Inc, New York!Chichester/Weinheim

4. N.K. Jain, Controlled and Novel Drug Delivery, CBS Publishers & Distributors,New Delhi, First edition 1997 (reprint in 2001).

5. S.P.Vyas and R.K.Khar, Controlled Drug Delivery - concepts and advances,VallabhPrakashan, New Delhi, First edition 2002

JOURNALS

1. Indian Journal of Pharmaceutical Sciences (IPA)
2. Indian drugs (IDMA)
3. Journal of controlled release (Elsevier Sciences) desirable
4. Drug Development and Industrial Pharmacy (Marcel & Decker) desirable

MPH 103T. MODERN PHARMACEUTICS

SCOPE: Course designed to impart advanced knowledge and skills required to learn various aspects and concepts at pharmaceutical industries

OBJECTIVES: Upon completion of the course, student shall be able to understand

- The elements of reformulation studies.
- The Active Pharmaceutical Ingredients and Generic drug Product development
- Industrial Management and GMP Considerations.
- Optimization Techniques & Pilot Plant Scale Up Techniques
- Stability Testing, sterilization process & packaging of dosage forms.

COURSE CONTENT

UNIT	CONTENT	No. of Hrs.
I	**a. Preformation Concepts** – Drug Excipient interactions - different methods, kinetics of stability, Stability testing. Theories of dispersion and pharmaceutical Dispersion (Emulsion and Suspension, SMEDDS) preparation and stability Large and small volume parental – physiological and formulation consideration, Manufacturing and evaluation. b. **Optimization techniques in Pharmaceutical Formulation**: Concept and parameters of optimization, Optimization techniques in pharmaceutical formulation and processing. Statistical design, Response surface method, Contour designs, Factorial designs and application in formulation	**20**
II	**Validation** : Introduction to Pharmaceutical Validation, Scope & merits of Validation, Validation and calibration of Master plan, ICH & WHO guidelines for calibration and validation of equipments, Validation of specific dosage form, Types of validation. Government regulation, Manufacturing Process Model, URS, DQ, IQ, OQ & P.Q. of facilities.	**10**

III	**cGMP& Industrial Management**: Objectives and policies of current good manufacturing practices, layout of buildings, services, equipments and their maintenance Production management: Production organization, , materials management, handling and transportation, inventory management and control, production and planning control, Sales forecasting, budget and cost control, industrial and personal relationship. Concept of Total Quality Management.	**10**
IV	**Compression and compaction**: Physics of tablet compression, compression, consolidation, effect of friction, distribution of forces, compaction profiles. Solubility.	**10**
V	**Study of consolidation parameters**; Diffusion parameters, Dissolution parameters and Pharmacokinetic parameters, Heckel plots, Similarity factors – f2 and f1, Higuchi and Peppas plot, Linearity Concept of significance, Standard deviation , Chi square test, students T-test , ANOVA test.	**10**

REFERENCES

1. Theory and Practice of Industrial Pharmacy ByLachmann and Libermann
2. Pharmaceutical dosage forms: Tablets Vol. 1-3 by Leon Lachmann.
3. Pharmaceutical Dosage forms: Disperse systems, Vol, 1-2; By LeonLachmann.
4. Pharmaceutical Dosage forms: Parenteral medications Vol. 1-2; By LeonLachmann.
5. Modern Pharmaceutics; By Gillbert and S. Banker.
6. Remington‟s Pharmaceutical Sciences.
7. Advances in Pharmaceutical Sciences Vol. 1-5; By H.S. Bean & A.H.Beckett.
8. Physical Pharmacy; By Alfred martin
9. Bentley‟s Textbook of Pharmaceutics – by Rawlins.
10. Good manufacturing practices for Pharmaceuticals: A plan for total qualitycontrol, Second edition; By Sidney H. Willig.
11. Quality Assurance Guide; By Organization of Pharmaceutical producers ofIndia.
12. Drug formulation manual; By D.P.S. Kohli and D.H.Shah. Easternpublishers, New Delhi.
13. How to practice GMPs; By P.P.Sharma. Vandhana Publications, Agra.
14. Pharmaceutical Process Validation; By Fra. R. Berry and Robert A. Nash.
15. Pharmaceutical Preformulations; By J.J. Wells.
16. Applied production and operations management; By Evans, Anderson,Sweeney and Williams.
17. Encyclopaedia of Pharmaceutical technology, Vol I – III.

MPH 104T. REGULATORY AFFAIRS

SCOPE: Course designed to impart advanced knowledge and skills required to learn the concept of generic drug and their development, various regulatory filings in different countries, different phases of clinical trials and submitting regulatory documents: filing process of IND, NDA and ANDA.

.**OBJECTIVES:** Upon completion of the course, student shall be able to understand

- The Concepts of innovator and generic drugs, drug development process
- The Regulatory guidance‟s and guidelines for filing and approval process
- Preparation of Dossiers and their submission to regulatory agencies in different countries
- Post approval regulatory requirements for actives and drug products
- Submission of global documents in CTD/ eCTD formats
- Clinical trials requirements for approvals for conducting clinical trials
- Pharmacovigilence and process of monitoring in clinical trials..

COURSE CONTENT

UNIT	CONTENT	No. of Hrs.
I	a. Documentation in Pharmaceutical industry: Master formula record, DMF (Drug Master File), distribution records. Generic drugs product development Introduction , Hatch- Waxman act and amendments, CFR (CODE OF FEDERAL REGULATION) ,drug product performance, in-vitro, ANDA regulatory approval process, NDA approval process, BE and drug product assessment, in –vivo, scale up process approval changes, post marketing surveillance, outsourcing BA and BE to CRO.	12
II	Regulatory requirement for product approval: API, biologics, novel, therapies obtaining NDA, ANDA for generic drugs ways and means of US registration for foreign drugs	12

III	CMC, post approval regulatory affairs. Regulation for combination products and medical devices.CTD and ECTD format, industry and FDA liaison. ICH - Guidelines of ICH-Q, S E, M. Regulatory requirements of EU, MHRA, TGA and ROW countries.	**12**
IV	Non clinical drug development: Global submission of IND, NDA, ANDA. Investigation of medicinal products dossier, dossier (IMPD) and investigator brochure (IB).	**12**
V	Clinical trials: Developing clinical trial protocols. Institutional review board/ independent ethics committee Formulation and working procedures informed Consent process and procedures. HIPAA- new, requirement to clinical study process, pharmacovigilance safety monitoring in clinical trials.	**12**

REFERENCES

1. Generic Drug Product Development, Solid Oral Dosage forms, Leon Shargeland IsaderKaufer,Marcel Dekker series, Vol.143
2. The Pharmaceutical Regulatory Process, Second Edition Edited by Ira R.Berry and Robert P.Martin, Drugs and the Pharmaceutical Sciences,Vol.185,Informa Health care Publishers.
3. New Drug Approval Process: Accelerating Global Registrations By Richard AGuarino, MD,5th edition, Drugs and the Pharmaceutical Sciences,Vol.190.
4. Guidebook for drug regulatory submissions / Sandy Weinberg. By John Wiley&Sons.Inc.
5. FDA regulatory affairs: a guide for prescription drugs, medical devices, andbiologics/edited By Douglas J. Pisano, David Mantus.
6. Clinical Trials and Human Research: A Practical Guide to RegulatoryCompliance By Fay A.Rozovsky and Rodney K. Adams
7. www.ich.org/
8. www.fda.gov/
9. europa.eu/index_en.htm
10. https://www.tga.gov.au/tga-basics

MPH105 P. PHARMACEUTICS PRACTICALS - I

1. Analysis of pharmacopoeial compounds and their formulations by UV Visspectrophotometer
2. Simultaneous estimation of multi component containing formulations by UVspectrophotometry
3. Experiments based on HPLC
4. Experiments based on Gas Chromatography
5. Estimation of riboflavin/quinine sulphate by fluorimetry
6. Estimation of sodium/potassium by flame photometry
7. To perform In-vitro dissolution profile of CR/ SR marketed formulation
8. Formulation and evaluation of sustained release matrix tablets
9. Formulation and evaluation osmotically controlled DDS
10. Preparation and evaluation of Floating DDS- hydro dynamically balancedDDS
11. Formulation and evaluation of Muco adhesive tablets.
12. Formulation and evaluation of trans dermal patches.
13. To carry out preformulation studies of tablets.
14. To study the effect of compressional force on tablets disintegration time.
15. To study Micromeritic properties of powders and granulation.
16. To study the effect of particle size on dissolution of a tablet.
17. To study the effect of binders on dissolution of a tablet.
18. To plot Heckal plot, Higuchi and peppas plot and determine similarityfactors.

MPH 201T. MOLECULAR PHARMACEUTICS (NANO TECHNOLOGY & TARGETED DDS) (NTDS)

SCOPE: This course is designed to impart knowledge on the area of advances in novel drug delivery systems.

OBJECTIVES: Upon completion of the course, student shall be able to understand

- The various approaches for development of novel drug delivery systems.
- The criteria for selection of drugs and polymers for the development of NTDS
- The formulation and evaluation of novel drug delivery systems.

COURSE CONTENT

UNIT	CONTENT	No. of Hrs.
I	Targeted Drug Delivery Systems: Concepts, Events and biological process involved in drug targeting. Tumor targeting and Brain specific delivery.	12
II	Targeting Methods: introduction preparation and evaluation. Nano Particles & Liposomes: Types, preparation and evaluation.	12
III	Micro Capsules / Micro Spheres: Types, preparation and evaluation , Monoclonal Antibodies ; preparation and application, preparation and application of Niosomes, Aquasomes, Phytosomes, Electrosomes.	12
IV	Pulmonary Drug Delivery Systems : Aerosols, propellents, ContainersTypes, preparation and evaluation, Intra Nasal Route Delivery systems; Types, preparation and evaluation.	12
V	Nucleic acid based therapeutic delivery system : Gene therapy, introduction (ex-vivo & in-vivo gene therapy). Potential target diseases for gene therapy (inherited disorder and cancer). Gene expression systems (viral and nonviral gene transfer). Liposomal gene delivery systems. Biodistribution and Pharmacokinetics. knowledge of therapeutic antisense molecules and aptamers as drugs of future.	12

References

1. Y W. Chien, Novel Drug Delivery Systems, 2nd edition, revised andexpanded,Marcel Dekker, Inc., New York, 1992.

2. S.P.Vyas and R.K.Khar, Controlled Drug Delivery - concepts andadvances, VallabhPrakashan, New Delhi, First edition 2002.

3. N.K. Jain, Controlled and Novel Drug Delivery, CBS Publishers &Distributors, NewDelhi, First edition 1997 (reprint in 2001).

MPH 202T. ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS

SCOPE: This course is designed to impart knowledge and skills necessary for dose calculations, dose adjustments and to apply biopharmaceutics theories in practical problem solving. Basic theoretical discussions of the principles of biopharmaceutics and pharmacokinetics are provided to help the students‟ to clarify the concepts.

.**OBJECTIVES:** Upon completion of the course, student shall be able to understand

- The basic concepts in biopharmaceutics and pharmacokinetics.
- The use raw data and derive the pharmacokinetic models and parameters the best describe the process of drug absorption, distribution, metabolism and elimination.
- The critical evaluation of biopharmaceutic studies involving drug product equivalency.
- The design and evaluation of dosage regimens of the drugs using pharmacokinetic and biopharmaceutic parameters.
- The potential clinical pharmacokinetic problems and application of basics of pharmacokinetic

COURSE CONTENT

Units	Contents	Hours
1	**Drug Absorption from the Gastrointestinal Tract:** Gastrointestinal tract, Mechanism of drug absorption, Factors affecting drug absorption, pH– partition theory of drug absorption. Formulation and physicochemical factors: Dissolution rate, Dissolution process, Noyes–Whitney equation and drug dissolution, Factors affecting the dissolution rate. Gastrointestinal absorption: role of the dosage form: Solution (elixir, syrup and solution) as a dosage form ,Suspension as a dosage form, Capsule as a dosage form, Tablet as a dosage form, Dissolution methods ,Formulation and processing factors Correlation of in vivo data with in vitro dissolution data.Transport model: Permeability-Solubility-Charge State and the pH Partition Hypothesis, Properties of the Gastrointestinal Tract (GIT), pH Microclimate Intracellular pH Environment, Tight-Junction Complex.	12
2	**Biopharmaceutic considerations in drug product design and In Vitro Drug ProducPerformance:** Introduction, biopharmaceutic factors affecting drug bioavailability, rate-limiting steps in drug absorption, Physicochemi cal nature of the drug formulation factors affecting drug product performance, in vitro: dissolution and drug release testing, compendial methods of dissolution, alternative methods of dissolution testing,meeting dissolution requirements,problems of variable control in dissolution testingperformance of drug products. In vitro–in vivo correlation, dissolution profile comparisons, drug product stability, considerations in the design of a drug product.	12

3	**Pharmacokinetics:** Basic considerations, pharmacokinetic models, compartment modeling: one compartment model- IV bolus, IV infusion, extra-vascular. Multi compartment model:two compartment - model in brief, non-linear pharmacokinetics: causeof non-linearity, Michaelis – Menten equation, estimation of kmax and vmax. Drug interactions: introduction, the effect of protein-binding interactions, the effect of tissue- binding interactions,cytochro me p450-based drug interactions, drug interactions linked to transporters.	12
4	**Drug Product Performance, In Vivo: Bioavailability and Bioequivalence:** drug product performance, purpose of bioavailability studies, relative and absolute availability. Methods for assessing bioavailability, bioequivalence studies, design and evaluation of bioequivalence studies, study designs, crossover study designs, evaluation of the data, bioequivalence example, study submission and drug review process. biopharmaceutics classification system, methods. Permeability: In- vitro, in-situ and In-vivo methods.generic biologics (biosimilar drug products), clinical significance of bioequivalence studies, special concerns in bioavailability and bioequivalence studies, generic substitution.	12
5	**Application of Pharmacokinetics:** Modified-Release Drug Products, Targeted Drug Delivery Systems and Biotechnological Products. Introduction to Pharmacokinetics and pharmacodynamic, drug interactions. Pharmacokinetics and pharmacodynamics of biotechnology drugs. Introduction, Proteins and peptides, Monoclonal antibodies, Oligonucleotides, Vaccines (immunotherapy), Gene therapies.	12

References

1. Biopharmaceutics and Clinical Pharmacokinetics by Milo Gibaldi, 4th edition, Philadelphia, Lea and Febiger, 1991
2. Biopharmaceutics and Pharmacokinetics, A. Treatise, D .M. Brahmankar and Sunil B. Jaiswal., VallabPrakashan, Pitampura, Delhi
3. Applied Biopharmaceutics and Pharmacokinetics by Shargel. Land YuABC, 2nd edition, Connecticut Appleton Century Crofts, 1985
4. Textbook of Biopharmaceutics and Pharmacokinetics, Dr. Shobha Rani R. Hiremath, Prism Book
5. Pharmacokinetics by Milo Gibaldi and D. Perrier, 2nd edition, Marcel Dekker Inc.,New York, 1982
6. Current Concepts in Pharmaceutical Sciences: Biopharmaceutics, Swarbrick. J, Leaand Febiger, Philadelphia, 1970
7. Clinical Pharmacokinetics, Concepts and Applications 3rd edition by Malcolm Rowland and Thom~ N. Tozer, Lea and Febiger, Philadelphia, 1995
8. Dissolution, Bioavailability and Bioequivalence, Abdou. H.M, Mack Publishing Company, Pennsylvania 1989
9. Biopharmaceutics and Clinical Pharmacokinetics, An Introduction, 4th edition, revised and expanded by Robert. E. Notari, Marcel Dekker Inc, New York and Basel,1987.
10. Biopharmaceutics and Relevant Pharmacokinetics by John. G Wagner and M. Pemarowski, 1st edition, Drug Intelligence Publications, Hamilton, Illinois, 1971.

11. Encyclopedia of Pharmaceutical Technology, Vol 13, James Swarbrick, James. G. Boylan, Marcel Dekker Inc, New York, 1996.
12. Basic Pharmacokinetics,1 st edition, Sunil S Jambhekar and Philip J Breen, pharmaceutical press, RPS Publishing,2009.
13. Absorption and Drug Development- Solubility, Permeability, and Charge State, Alex Avdeef, John Wiley & Sons, Inc,2003.

MPH 203T. COMPUTER AIDED DRUG DEVELOPMENT

SCOPE: This course is designed to impart knowledge and skills necessary for computer Applications in pharmaceutical research and development who want to understand the application of computers across the entire drug research and development process. Basic theoretical discussions of the principles of more integrated and coherent use of computerized information (informatics) in the drug development process are provided to help the students to clarify the concepts. .**OBJECTIVES:** Upon completion of the course, student shall be able to understand

- History of Computers in Pharmaceutical Research and Development
- Computational Modeling of Drug Disposition
- Computers in Preclinical Development
- Optimization Techniques in Pharmaceutical Formulation
- Computers in Market Analysis
- Computers in Clinical Development
- Artificial Intelligence (AI) and Robotics
- Computational fluid dynamics(CFD

COURSE CONTENT

UNIT	CONTENT	No. of Hrs.
I	a. **Computers in Pharmaceutical Research and Development:** A General Overview: History of Computers in Pharmaceutical Research and Development. Statistical modeling in Pharmaceutical research and development: Descriptive versus Mechanistic Modeling, Statistical Parameters, Estimation, Confidence Regions, Nonlinearity at the Optimum, Sensitivity Analysis, Optimal Design, Population Modeling b. **Quality-by-Design In Pharmaceutical Development:** Introduction, ICH Q8 guideline, Regulatory and industry views on QbD, Scientifically based QbD - examples of application.	**12**

II	**Computational Modeling Of Drug Disposition:** Introduction ,Modeling Techniques: Drug Absorption, Solubility, Intestinal Permeation, Drug Distribution ,Drug Excretion, Active Transport; P-gp, BCRP, Nucleoside Transporters, hPEPT1, ASBT, OCT, OATP, BBB-Choline Transporter.	**12**
III	**Computer-aided formulation development:** Concept of optimization, Optimization parameters, Factorial design, Optimization technology & Screening design. Computers in Pharmaceutical Formulation: Development of pharmaceutical emulsions, microemulsion drug carriers Legal Protection of Innovative Uses of Computers in R&D, The Ethics of Computing in Pharmaceutical Research, Computers in Market analysis	**12**
IV	a. **Computer-aided biopharmaceutical characterization:** Gastrointestinal absorption simulation. Introduction, Theoretical background, Model construction, Parameter sensitivity analysis, Virtual trial, Fed vs. fasted state, In vitro dissolution and in vitro-in vivo correlation, Biowaiver considerations b. **Computer Simulations in Pharmacokinetics and Pharmacodynamics:** Introduction, Computer Simulation: Whole Organism, Isolated Tissues, Organs, Cell, Proteins and Genes. c. **Computers in Clinical Development:** Clinical Data Collection and Management, Regulation of Computer Systems	**12**
V	V **Artificial Intelligence (AI), Robotics and Computational fluid dynamics: 12** General overview, Pharmaceutical Automation, Pharmaceutical applications, Advantages and Disadvantages. Current Challenges and Future Directions.	**12**

REFERENCES

1. Computer Applications in Pharmaceutical Research and Development,Sean Ekins, 2006, John Wiley & Sons.

2. Computer-Aided Applications in Pharmaceutical Technology, 1st Edition,JelenaDjuris, Woodhead Publishing

3. Encyclopedia of Pharmaceutical Technology, Vol 13, James Swarbrick,James. G.Boylan, Marcel Dekker Inc, New York, 1996.

MPH 204T. COSMETICS AND COSMECEUTICALS

SCOPE: This course is designed to impart knowledge and skills necessary for the fundamental need for cosmetic and cosmeceutical products.

.**OBJECTIVES:** Upon completion of the course, student shall be able to understand

- Key ingredients used in cosmetics and cosmeceuticals.
- Key building blocks for various formulations.
- Current technologies in the market
- Various key ingredients and basic science to develop cosmetics and cosmeceuticals
- Scientific knowledge to develop cosmetics and cosmeceuticals with desired Safety, stability, and efficacy.

COURSE CONTENT

UNIT	CONTENT	No. of Hrs.
I	**Cosmetics – Regulatory :** Definition of cosmetic products as per Indian regulation. Indian regulatory requirements for labeling of cosmetics Regulatory provisions relating to import of cosmetics., Misbranded and spurious cosmetics. Regulatory provisions relating to manufacture of cosmetics – Conditions for obtaining license, prohibition of manufacture and sale of certain cosmetics, loan license, offences and penalties.	**12**
II	**Cosmetics - Biological aspects :** Structure of skin relating toproblems like dry skin, acne, pigmentation, prickly heat, wrinkles and body odor. Structure of hair and hair growth cycle. Common problems associated with oral cavity. Cleansing and care needs for face, eye lids, lips, hands, feet, nail, scalp, neck, body and under-arm.	**12**
III	**Formulation Building blocks:** Building blocks for different product formulations of cosmetics/cosmeceuticals. Surfactants – Classification and	**12**

	application. Emollients, rheological additives: classification and application. Antimicrobial used as preservatives, their merits and demerits. Factors affecting microbial preservative efficacy. Building blocks for formulation of a moisturizing cream,vanishing cream, cold cream, shampoo and toothpaste. Soaps and syndetbars. Perfumes; Classification of perfumes. Perfume ingredients listed as allergens in EU regulation. Controversial ingredients: Parabens, formaldehyde liberators, dioxane	
IV	**Design of cosmeceutical products:** Sun protection, sunscreens classification and regulatory aspects. Addressing dry skin, acne, sun-protection, pigmentation, prickly heat, wrinkles, body odor., dandruff, dental cavities, bleeding gums, mouth odor and sensitive teeth through cosmeceutical formulations.	**12**
V	**Herbal Cosmetics :** Herbal ingredients used in Hair care, skin care and oral care. Review of guidelines for herbal cosmetics by private bodies like cosmos with respect to preservatives, emollients, foaming agents, emulsifiers and rheology modifiers. Challenges in formulating herbal cosmetics.	**12**

REFERENCES

1. Harry"s Cosmeticology. 8th edition.
2. Poucher"sperfumecosmeticsandSoaps,10th edition.
3. Cosmetics - Formulation, Manufacture and quality control, PP.Sharma,4th edition
4. Handbook of cosmetic science and Technology A.O.Barel, M.Paye andH.I. Maibach. 3 rd edition
5. Cosmetic and Toiletries recent suppliers catalogue.
6. CTFA directory.

MPH 205P. PHARMACEUTICS PRACTICAL – II

1. To study the effect of temperature change , non solvent addition,incompatible polymer addition in microcapsules preparation
2. Preparation and evaluation of Alginate beads
3. Formulation and evaluation of gelatin /albumin microspheres
4. Formulation and evaluation of liposomes/niosomes
5. Formulation and evaluation of spherules
6. Improvement of dissolution characteristics of slightly soluble drug by Soliddispersion technique.
7. Comparison of dissolution of two different marketed products /brands
8. Protein binding studies of a highly protein bound drug & poorly proteinbound drug
9. Bioavailability studies of Paracetamol in animals.
10. Pharmacokinetic and IVIVC data analysis by WinnolineR software
11. In vitro cell studies for permeability and metabolism
12. DoE Using Design Expert® Software
13. Formulation data analysis Using Design Expert® Software
14. Quality-by-Design in Pharmaceutical Development
15. Computer Simulations in Pharmacokinetics and Pharmacodynamics
16. Computational Modeling Of Drug Disposition
17. To develop Clinical Data Collection manual
18. To carry out Sensitivity Analysis, and Population Modeling.
19. Development and evaluation of Creams
20. Development and evaluation of Shampoo and Toothpaste base
21. To incorporate herbal and chemical actives to develop products
22. To address Dry skin, acne, blemish, Wrinkles, bleeding gums anddandruff

3rd SEMESTER

MRM301T - RESEARCH METHODOLOGY & BIOSTATISTICS

Course Outcome

At the end of the course students will be able to…

CO1	Learn general research methodology
CO2	Understand the basic concepts of biostatistics
CO3	Learn different parametric and non-parametric tests
CO4	Understand the functions of ethics committees in medical research
CO5	Learn the guidelines for developing animal facilities
CO6	Explain the guidelines and importance of medical research
CO7	Learn the guidelines for the experimentation on animals
CO8	Understand the genesis of bioethics with special reference to Helsinkl declaration

COURSE CONTENT

UNIT – I

General Research Methodology: Research, objective, requirements, practical difficulties, review of literature, study design, types of studies, strategies to eliminate errors/bias, controls, randomization, crossover design, placebo, blinding techniques.

UNIT – II

Biostatistics: Definition, application, sample size, importance of sample size, factors influencing sample size, dropouts, statistical tests of significance, type of significance tests, parametric tests (students "t" test, ANOVA, Correlation coefficient, regression), non- parametric tests (wilcoxan rank tests, analysis of variance, correlation, chi square test), null hypothesis, P values, degree of freedom, interpretation of P values.

UNIT – III

Medical Research: History, values in medical ethics, autonomy, beneficence, non-maleficence, double effect, conflicts between autonomy and beneficence/non-maleficence, euthanasia, informed consent, confidentiality, criticisms of orthodox medical ethics, importance of communication, control resolution, guidelines, ethics committees, cultural concerns, truth telling, online business practices, conflicts of interest, referral, vendor relationships, treatment of family members, sexual relationships, fatality.

UNIT – IV

CPCSEA guidelines for laboratory animal facility: Goals, veterinary care, quarantine, surveillance, diagnosis, treatment and control of disease, personal hygiene, location of animal facilities to laboratories, anesthesia, euthanasia, physical facilities, environment, animal husbandry, record keeping, SOPs, personnel and training, transport of lab animals.

UNIT – V

Declaration of Helsinki: History, introduction, basic principles for all medical research, and additional principles for medical research combined with medical care.